<p>文藝復興科技公司在其最近向美國證券交易委員會提交的 13F 文件中表示，在第四季度將其在 Aerovate Therapeutics, Inc.（納斯達克：AVTE - 免費報告）股票中的持股比例提高了 149.2%。該公司在本季度額外購買了 26,700 股後，持有 44,600 股該公司的股票。根據其最近的 SEC 文件，文藝復興科技公司持有 Aerovate Therapeutics 0.15% 的股份，價值 118,000 美元。</p>
<p>獲取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
<p>其他機構投資者也增加或減少了在該公司的持股。ADAR1 Capital Management LLC 在第四季度將其在 Aerovate Therapeutics 的持股比例提高了 720.7%。ADAR1 Capital Management LLC 現在擁有 928,016 股該公司的股票，價值 2,459,000 美元，此前在該期間內額外購買了 814,941 股。蒙特利爾銀行在第四季度將其在 Aerovate Therapeutics 的持股比例提高了 86.8%。蒙特利爾銀行現在擁有 59,097 股該公司的股票，價值 157,000 美元，此前在上個季度額外購買了 27,453 股。拉塞爾投資集團有限公司在第四季度將其在 Aerovate Therapeutics 的持股比例提高了 110.7%。拉塞爾投資集團有限公司現在擁有 15,184 股該公司的股票，價值 40,000 美元，此前在上個季度額外購買了 7,977 股。摩根大通在第四季度將其在 Aerovate Therapeutics 的持股比例提高了 1,021.1%。摩根大通現在擁有 67,165 股該公司的股票，價值 178,000 美元，此前在上個季度額外購買了 61,174 股。最後，Corient Private Wealth LLC 在第四季度購買了 Aerovate Therapeutics 的新股份，價值約 98,000 美元。</p>
<h2>Aerovate Therapeutics 價格表現</h2>
<p>Aerovate Therapeutics 的股票在週四開盤價為 10.09 美元。Aerovate Therapeutics, Inc.的 1 年最低價為 43.75 美元，1 年最高價為 884.98 美元。該公司的市值為 2.9246 億美元，市盈率為-3.37，貝塔值為 0.95。該公司的 50 日簡單移動平均線為 78.40 美元，200 日簡單移動平均線為 85.32 美元。</p>
<p>Aerovate Therapeutics（納斯達克：AVTE - 獲取免費報告）最後一次發佈財報是在 4 月 25 日，週五。該公司報告本季度每股收益（EPS）為-3.15 美元，超出分析師一致預期的-10.50 美元，差額為 7.35 美元。整體來看，研究分析師預計 Aerovate Therapeutics, Inc.在當前年度的每股收益為-2.64 美元。</p>
<h2>Aerovate Therapeutics 宣佈分紅</h2>
<p>該公司最近還披露了一項分紅，已於 4 月 28 日（週一）支付。4 月 25 日（週五）登記在冊的股東獲得了 84.00 美元的分紅。除息日期為 4 月 29 日（週二）。</p>
<h2>Aerovate Therapeutics 公司簡介</h2>
<p>（免費報告）</p>
<p>Aerovate Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發能夠改善美國罕見心肺疾病患者生活的藥物。它專注於推進 AV-101，這是一種用於治療肺動脈高壓的乾粉吸入劑，目前處於 2b/3 期臨牀試驗中。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Aerovate Therapeutics</li>
<li>投資股票的不同類型</li>
<li>調查：美國最具啓發性的女性商業領袖 [2025]</li>
<li>房地產投資信託是否值得在你的投資組合中佔有一席之地？</li>
<li>迪士尼股票因財報上漲——這種魔力能持續嗎？</li>
<li>如何投資生物科技股票</li>
<li>油價、價值和增長的相關性對市場的影響</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Aerovate Therapeutics 嗎？</h2>
<p>在你考慮 Aerovate Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Aerovate Therapeutics 並不在名單上。</p>
<p>雖然 Aerovate Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

AVTE

<p>文藝復興科技公司（Renaissance Technologies LLC）在 2023 年第四季度將其在 Aerovate Therapeutics, Inc.（NASDAQ:AVTE）的持股增加了 149.2%，額外購買了 26,700 股，使其總持股達到 44,600 股，價值 118,000 美元。其他機構投資者也顯著增加了他們的持倉。Aerovate 的股票開盤價為 10.09 美元，市值為 2.9246 億美元，市盈率為-3.37。該公司最近報告的每股收益（EPS）為-3.15，超出預期，並宣佈將於 4 月 28 日支付 84.00 美元的股息</p>

<p>Renaissance Technologies LLC lifted its stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 149.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 44,600 shares of the company's stock after purchasing an additional 26,700 shares during the quarter. Renaissance Technologies LLC owned 0.15% of Aerovate Therapeutics worth $118,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>文藝復興科技公司在其最近向美國證券交易委員會提交的 13F 文件中表示，在第四季度將其在 Aerovate Therapeutics, Inc.（納斯達克：AVTE - 免費報告）股票中的持股比例提高了 149.2%。該公司在本季度額外購買了 26,700 股後，持有 44,600 股該公司的股票。根據其最近的 SEC 文件，文藝復興科技公司持有 Aerovate Therapeutics 0.15% 的股份，價值 118,000 美元。</p>
</div><p>Get <strong>Aerovate Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
</div><p>Other institutional investors have also added to or reduced their stakes in the company. ADAR1 Capital Management LLC boosted its position in shares of Aerovate Therapeutics by 720.7% in the fourth quarter. ADAR1 Capital Management LLC now owns 928,016 shares of the company's stock valued at $2,459,000 after acquiring an additional 814,941 shares during the period. Bank of Montreal Can grew its position in shares of Aerovate Therapeutics by 86.8% during the 4th quarter. Bank of Montreal Can now owns 59,097 shares of the company's stock valued at $157,000 after purchasing an additional 27,453 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Aerovate Therapeutics by 110.7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,184 shares of the company's stock valued at $40,000 after acquiring an additional 7,977 shares in the last quarter. JPMorgan Chase &amp; Co. boosted its position in shares of Aerovate Therapeutics by 1,021.1% during the 4th quarter. JPMorgan Chase &amp; Co. now owns 67,165 shares of the company's stock valued at $178,000 after acquiring an additional 61,174 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new position in shares of Aerovate Therapeutics in the fourth quarter worth approximately $98,000.</p>
<div class="lb-trans"><p>其他機構投資者也增加或減少了在該公司的持股。ADAR1 Capital Management LLC 在第四季度將其在 Aerovate Therapeutics 的持股比例提高了 720.7%。ADAR1 Capital Management LLC 現在擁有 928,016 股該公司的股票，價值 2,459,000 美元，此前在該期間內額外購買了 814,941 股。蒙特利爾銀行在第四季度將其在 Aerovate Therapeutics 的持股比例提高了 86.8%。蒙特利爾銀行現在擁有 59,097 股該公司的股票，價值 157,000 美元，此前在上個季度額外購買了 27,453 股。拉塞爾投資集團有限公司在第四季度將其在 Aerovate Therapeutics 的持股比例提高了 110.7%。拉塞爾投資集團有限公司現在擁有 15,184 股該公司的股票，價值 40,000 美元，此前在上個季度額外購買了 7,977 股。摩根大通在第四季度將其在 Aerovate Therapeutics 的持股比例提高了 1,021.1%。摩根大通現在擁有 67,165 股該公司的股票，價值 178,000 美元，此前在上個季度額外購買了 61,174 股。最後，Corient Private Wealth LLC 在第四季度購買了 Aerovate Therapeutics 的新股份，價值約 98,000 美元。</p>
</div><h2>Aerovate Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 價格表現</h2>
</div><p>Shares of Aerovate Therapeutics stock opened at $10.09 on Thursday. Aerovate Therapeutics, Inc. has a 1 year low of $43.75 and a 1 year high of $884.98. The firm has a market cap of $292.46 million, a PE ratio of -3.37 and a beta of 0.95. The company has a 50 day simple moving average of $78.40 and a two-hundred day simple moving average of $85.32.</p>
<div class="lb-trans"><p>Aerovate Therapeutics 的股票在週四開盤價為 10.09 美元。Aerovate Therapeutics, Inc.的 1 年最低價為 43.75 美元，1 年最高價為 884.98 美元。該公司的市值為 2.9246 億美元，市盈率為-3.37，貝塔值為 0.95。該公司的 50 日簡單移動平均線為 78.40 美元，200 日簡單移動平均線為 85.32 美元。</p>
</div><p>Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last released its earnings results on Friday, April 25th. The company reported ($3.15) EPS for the quarter, beating analysts' consensus estimates of ($10.50) by $7.35. As a group, research analysts anticipate that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current year.</p>
<div class="lb-trans"><p>Aerovate Therapeutics（納斯達克：AVTE - 獲取免費報告）最後一次發佈財報是在 4 月 25 日，週五。該公司報告本季度每股收益（EPS）為-3.15 美元，超出分析師一致預期的-10.50 美元，差額為 7.35 美元。整體來看，研究分析師預計 Aerovate Therapeutics, Inc.在當前年度的每股收益為-2.64 美元。</p>
</div><h2>Aerovate Therapeutics Announces Dividend</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 宣佈分紅</h2>
</div><p>The firm also recently disclosed a dividend, which was paid on Monday, April 28th. Stockholders of record on Friday, April 25th were issued a $84.00 dividend. The ex-dividend date was Tuesday, April 29th.</p>
<div class="lb-trans"><p>該公司最近還披露了一項分紅，已於 4 月 28 日（週一）支付。4 月 25 日（週五）登記在冊的股東獲得了 84.00 美元的分紅。除息日期為 4 月 29 日（週二）。</p>
</div><h2>Aerovate Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發能夠改善美國罕見心肺疾病患者生活的藥物。它專注於推進 AV-101，這是一種用於治療肺動脈高壓的乾粉吸入劑，目前處於 2b/3 期臨牀試驗中。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Aerovate Therapeutics</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Survey: America’s Most Inspirational Women Business Leaders [2025]</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>Disney Stock Jumps on Earnings—Is the Magic Sustainable?</li>
<li>How to Invest in Biotech Stocks</li>
<li>What Oil, Value, and Growth Correlations Say About the Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Aerovate Therapeutics</li>
<li>投資股票的不同類型</li>
<li>調查：美國最具啓發性的女性商業領袖 [2025]</li>
<li>房地產投資信託是否值得在你的投資組合中佔有一席之地？</li>
<li>迪士尼股票因財報上漲——這種魔力能持續嗎？</li>
<li>如何投資生物科技股票</li>
<li>油價、價值和增長的相關性對市場的影響</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AVTE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aerovate Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Aerovate Therapeutics 嗎？</h2>
</div><p>Before you consider Aerovate Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Aerovate Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Aerovate Therapeutics 並不在名單上。</p>
</div><p>While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Aerovate Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

文藝復興科技有限責任公司購入了 Aerovate Therapeutics, Inc.（納斯達克股票代碼：AVTE）的 26,700 股股票